Actavis At 5: Where Pay-For-Delay Litigation Stands
Law360 (August 6, 2018, 6:47 PM EDT) -- It’s been a little over five years since the U.S. Supreme Court issued its landmark Actavis decision that found payments made by brand-name drugmakers to generics makers in patent settlements can raise antitrust concerns. But uncertainty over which pay-for-delay deals actually are illegal continues and recent lower court rulings have cut both ways, with some cases fizzling out and others forging ahead.
Here, Law360 looks at some of those recent rulings and where pay-for-delay litigation currently stands.
Case: In re: Loestrin 24 Fe Antitrust Litigation
Court: District of Rhode Island
Drug: Loestrin, oral contraceptive
Status: Discovery, awaiting ruling on...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!